JP7150999B2 - 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法 - Google Patents

植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法 Download PDF

Info

Publication number
JP7150999B2
JP7150999B2 JP2021548219A JP2021548219A JP7150999B2 JP 7150999 B2 JP7150999 B2 JP 7150999B2 JP 2021548219 A JP2021548219 A JP 2021548219A JP 2021548219 A JP2021548219 A JP 2021548219A JP 7150999 B2 JP7150999 B2 JP 7150999B2
Authority
JP
Japan
Prior art keywords
protein
toxin
binder
cleavable
plant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518614A (ja
Inventor
ベルトラン マギー
マックス ウーリー
Original Assignee
エーティービー セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーティービー セラピューティクス filed Critical エーティービー セラピューティクス
Publication of JP2022518614A publication Critical patent/JP2022518614A/ja
Priority to JP2022119504A priority Critical patent/JP7728587B2/ja
Application granted granted Critical
Publication of JP7150999B2 publication Critical patent/JP7150999B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021548219A 2019-02-18 2020-02-18 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法 Active JP7150999B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022119504A JP7728587B2 (ja) 2019-02-18 2022-07-27 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19157839.2 2019-02-18
EP19157839 2019-02-18
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022119504A Division JP7728587B2 (ja) 2019-02-18 2022-07-27 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Publications (2)

Publication Number Publication Date
JP2022518614A JP2022518614A (ja) 2022-03-15
JP7150999B2 true JP7150999B2 (ja) 2022-10-11

Family

ID=65717705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548219A Active JP7150999B2 (ja) 2019-02-18 2020-02-18 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法
JP2022119504A Active JP7728587B2 (ja) 2019-02-18 2022-07-27 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022119504A Active JP7728587B2 (ja) 2019-02-18 2022-07-27 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Country Status (11)

Country Link
US (1) US20220090113A1 (https=)
EP (2) EP3927831B1 (https=)
JP (2) JP7150999B2 (https=)
KR (1) KR102398485B1 (https=)
CN (2) CN113728107B (https=)
BR (1) BR112021016348A2 (https=)
CA (1) CA3128793C (https=)
ES (1) ES3055338T3 (https=)
IL (1) IL285719B (https=)
WO (1) WO2020169620A1 (https=)
ZA (1) ZA202105654B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022176933A (ja) * 2019-02-18 2022-11-30 エーティービー セラピューティクス 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021241719A1 (ja) * 2020-05-28 2021-12-02 中外製薬株式会社 改良されたグランザイムｂ改変体
CA3187245A1 (en) 2020-08-17 2022-02-24 Sebastien Mercx Recombinant immunotoxin comprising a ribotoxin or rnase
WO2022225329A1 (ko) * 2021-04-20 2022-10-27 고려대학교 산학협력단 향상된 암세포 사멸효능을 갖는 비대칭 항체
IL314969A (en) 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064815A1 (en) 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
JP2017043620A (ja) 2010-04-30 2017-03-02 エスペランス ファーマシューティカルズ， インコーポレイテッド 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
WO2003103605A2 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CN102933712A (zh) 2010-06-09 2013-02-13 纳幕尔杜邦公司 用于在植物中调节转基因表达的调控序列
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
JP7150999B2 (ja) * 2019-02-18 2022-10-11 エーティービー セラピューティクス 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064815A1 (en) 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
JP2017043620A (ja) 2010-04-30 2017-03-02 エスペランス ファーマシューティカルズ， インコーポレイテッド 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRANCISCO, J. A. et al.，Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture，Bioconjugate Chem. ，1997年，Vol. 8，P. 708-713
TRAN, M. et al.，Production of unique immunotoxin cancer therapeutics in algal chloroplasts，PNAS，2013年，Vol. 110, No. 1，E15-E22
WANG, T. et al.，Recombinant Immunoproapoptotic Proteins with Furin Site Can Translocate and Kill HER2-Positive Cancer Cells ，Cancer Res ，2007年，Vol. 67. No. 24，P. 11830-11839

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022176933A (ja) * 2019-02-18 2022-11-30 エーティービー セラピューティクス 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法
JP7728587B2 (ja) 2019-02-18 2025-08-25 エーティービー セラピューティクス 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法

Also Published As

Publication number Publication date
BR112021016348A2 (pt) 2021-11-23
IL285719B (en) 2022-07-01
JP2022176933A (ja) 2022-11-30
KR102398485B1 (ko) 2022-05-16
JP7728587B2 (ja) 2025-08-25
US20220090113A1 (en) 2022-03-24
CN113728107B (zh) 2022-06-24
IL285719A (en) 2021-10-31
ES3055338T3 (en) 2026-02-11
EP4733324A2 (en) 2026-04-29
EP3927831B1 (en) 2025-11-12
CA3128793A1 (en) 2020-08-27
CA3128793C (en) 2023-02-28
JP2022518614A (ja) 2022-03-15
EP3927831C0 (en) 2025-11-12
EP3927831A1 (en) 2021-12-29
CN115925972A (zh) 2023-04-07
CN113728107A (zh) 2021-11-30
KR20210120051A (ko) 2021-10-06
ZA202105654B (en) 2023-04-26
WO2020169620A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7150999B2 (ja) 植物細胞または植物全体においてバインダー‐毒素融合タンパク質を産生する方法
Conley et al. Optimization of elastin‐like polypeptide fusions for expression and purification of recombinant proteins in plants
Rodríguez et al. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor
Marusic et al. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells
Krittanai et al. Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody
CA2987490A1 (en) Nucleic acid molecule and uses thereof
US20090041776A1 (en) Production of cancer-specific antibodies in plants
Wang et al. Expression of bioactive anti-CD20 antibody fragments and induction of ER stress response in Arabidopsis seeds
WO2022038152A1 (en) Recombinant immunotoxin comprising a ribotoxin or rnase
US20250387478A1 (en) Recombinant immunotoxin comprising a ribosome inactivating protein
Zagorskaya et al. Recombinant monoclonal antibodies synthesized in plant expression systems: problems and prospects
CN101426814A (zh) 组合物和用于植物中n聚糖的人源化和最优化的方法
JP2025530642A (ja) ＣＤ７９ｂに対するヒト化抗体
Westerhof Plants as a production platform for high-value proteins
Lombardi Plant production of a tumour-targeting human IgG. Considerations on expression strategies, glycosylation profile and in planta proteolysis
Schouten Plantibodies: requirements for expression and subcellular targeting

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220928

R150 Certificate of patent or registration of utility model

Ref document number: 7150999

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250